- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04711135
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)
Study Overview
Status
Intervention / Treatment
Detailed Description
The study schedule for each patient consists of the screening period (up to 2 weeks) followed by the treatment period (4 treatment administrations at 8-week interval), and the follow-up period (5 years).
The treatment period will consist of 4 Lutathera treatments administered at 8-week intervals. Lutathera administration will occur on Week 1 Day 1 of each cycle. Each patient will receive a total of 4 doses of Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi). An infusion of 2.5% Lysine - Arginine amino acid (AA) solution will be co-administered with each Lutathera dose for renal protection according to the approved Lutathera local prescribing information. An antiemetic will be administered prior to infusion of the AA solution for prevention of infusion-related nausea and vomiting.
The dosimetry and PK assessments will be performed during the first week after the 1st Lutathera dose, i.e. one time during the study treatment period for each patient. The dosimetry analysis will allow for estimation from the 1st Lutathera administration of the cumulative absorbed radiation dose from 4 Lutathera doses and also for taking a decision on the next dose levels. In the exceptional circumstances when dosimetry cannot be performed in a particular patient after the first Lutathera dose, it should be completed as soon as feasible upon a later dose. In order to minimize risk for each study subject, an accelerated analysis of dosimetry and safety data will be performed for each patient in the study, to enable the Investigator to take a decision for the subsequent Lutathera doses. The results of dosimetry assessments (imaging and blood dosimetry) will be provided to the investigators for their evaluation prior to administration of subsequent therapeutic cycles in each patient.
A total follow-up period of 5 years (60 months) after the last Lutathera dose will take place for each patient who received at least one dose of Lutathera. This follow-up period will be comprised of a short-term follow-up of 6 months to evaluate cumulative Lutathera toxicities, followed by a long-term follow up of another 54 months.
An external Data and Safety Monitoring Board (DSMB) will also operate in the study to evaluate accumulating safety and dosimetry data, to ensure the safety of adolescents enrolled in the study, and to provide recommendations to investigators as well as to the clinical team in charge of conducting the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: 1-888-669-6682
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
Study Locations
-
-
-
Lyon, France
- Centre Leon Berard
-
-
-
-
-
Gliwice, Poland
- Maria Sklodowska-Curie National Research Institute of Oncology
-
-
-
-
-
Barcelona, Spain
- Hospital Universitari Vall d'Hebron
-
-
-
-
-
London, United Kingdom
- University College Hospital of London
-
-
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3039
- Cincinnati CHildren's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
GEP-NET cohort: presence of metastasized or locally advanced, inoperable (curative intent), histologically proven, G1 or G2 (Ki-67 index =< 20%), well differentiated GEP-NET.
or PPGL cohort: presence of metastasized or locally advanced, inoperable (curative intent), histologically proven PPGL.
- Patients from 12 to < 18 years of age at the time of enrollment.
- Expression of somatostatin receptors confirmed by a somatostatin receptor imaging (SRI) modality within 3 months prior to enrollment, with tumor uptake observed in the target lesions more or equal to the normal liver uptake.
- Performance status as determined by Karnofsky score >= 50 or Lansky Play-Performance Scale score >= 50.
- Parent's ability to understand and the willingness to sign a written informed consent document for adolescents as determined by local regulations. Adolescents will sign assent along with parental/legal guardian consent or will co-sign consent with parent/legal guardian in accordance with local regulation, prior to participation in the study.
Key Exclusion Criteria:
Laboratory parameters:
- Estimated creatinine clearance calculated by the Cockroft-Gault method < 70 mL/min
- Hb concentration <5.0 mmol/L (<8.0 g/dL); WBC <2x109/L; platelets <75x109/L.
- Total bilirubin >3 x ULN for age.
- Serum albumin <3.0 g/dL unless prothrombin time is within the normal range.
- Established or suspected pregnancy.
- Breastfeeding female patients unless they accept to discontinue breastfeeding from the 1st dose until 3 months after the last administration of study drug.
- Female patients of child-bearing potential, unless they are using highly effective methods of contraception during treatment and for 6 months after the last dose of Lutathera.
- Sexually active male patients, unless they agree to remain abstinent or be willing to use effective methods of contraception.
- Patients for whom in the opinion of the investigator other therapeutic options are considered more appropriate than the therapy offered in the study, based on patient and disease characteristics.
- Current spontaneous urinary incontinence.
- Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years.
- Hypersensitivity to the study drug active substance or to any of the excipients.
- Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with the completion of the study.
- Patient with known incompatibility to CT Scans with I.V. contrast due to allergic reaction or renal insufficiency. If such a patient can be imaged with MRI, then the patient would not be excluded.
- Patients who received any investigational agent within the last 30 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GEP-NET and PPGL
All eligible participants will receive Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi), with a concomitant administration of 2.5% Lysine - Arginine amino acid solution.
|
Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absorbed radiation doses in target organ
Time Frame: Up to 8 days after the first Lutetium [Lu 177] dotatate dose
|
Absorbed radiation doses in target organ (e.g.
kidney and bone marrow) will be evaluated when all GEP-NET patients have completed the 1st treatment of Lutathera and completed the dosimetry assessment.
|
Up to 8 days after the first Lutetium [Lu 177] dotatate dose
|
Incidence of adverse events (AEs) after the 1st treatment cycle
Time Frame: Up to 8 weeks after the first Lutetium [Lu 177] dotatate dose
|
The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.
|
Up to 8 weeks after the first Lutetium [Lu 177] dotatate dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events (AEs) during the short-term follow-up
Time Frame: Up to 6 months after the last Lutetium [Lu 177] dotatate dose
|
Cumulative safety of Lutathera in adolescents with SSTR-positive GEP-NETs will be assessed through the incidence of adverse events (AEs) and laboratory toxicities until 6 months after the last Lutathera dose.
|
Up to 6 months after the last Lutetium [Lu 177] dotatate dose
|
Incidence of adverse events (AEs) during the long term follow-up
Time Frame: Up to 5 years after the last Lutetium [Lu 177] dotatate dose
|
Long-term safety of Lutathera in adolescents with SSTR-positive GEP-NETs will be evaluated through the incidence of AEs and laboratory abnormalities during the 5-year follow-up after the last Lutathera dose.
|
Up to 5 years after the last Lutetium [Lu 177] dotatate dose
|
Comparative assessment of organ absorbed doses in adolescents and adults
Time Frame: Up to 8 days after the first Lutetium [Lu 177] dotatate dose
|
Calculated organ absorbed doses based on imaging radioactivity concentration data from adolescent with SSTR-positive GEP-NETs patients will be compared to the predicted distribution/organ absorbed doses in adult population.
|
Up to 8 days after the first Lutetium [Lu 177] dotatate dose
|
Maximum plasma concentration (Cmax) of Lutetium [Lu 177] dotatate in adolescents and adults
Time Frame: Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
Cmax will be listed and summarized using descriptive statistics.
|
Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Time of observed drug concentration occurrence (Tmax) of Lutetium [Lu 177] dotatate in adolescents and adults
Time Frame: Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
Tmax will be listed and summarized using descriptive statistics.
|
Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Area Under plasma concentration-time Curve from time 0 to 72 hours (AUC0-72) of Lutetium [Lu 177] dotatate in adolescents and adults
Time Frame: Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
AUC0-72 will be listed and summarized using descriptive statistics.
|
Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Total systemic clearance for intravenous administration (CL) of Lutetium [Lu 177] dotatate in adolescents and adults
Time Frame: Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
CL will be listed and summarized using descriptive statistics.
|
Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Volume of distribution in the central compartment (V1) of Lutetium [Lu 177] dotatate in adolescents and adults
Time Frame: Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
V1 will be listed and summarized using descriptive statistics.
|
Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Volume of distribution in the peripheral compartment (V2) of Lutetium [Lu 177] dotatate in adolescents and adults
Time Frame: Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization.
V2 will be listed and summarized using descriptive statistics.
|
Day 1 (0, 2, 6 hours post infusion), Day 2 (24 hours post infusion), Day 4 (72 hours post infusion)
|
Collaborators and Investigators
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAAA601A32201
- 2020-002951-39 (EudraCT Number)
- EMEA-002950-PIP01-20 (Other Identifier: EMA paediatric Investigation plan number(s) (PIP))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pheochromocytoma
-
National Cancer Institute (NCI)RecruitingMetastatic Adrenal Gland Pheochromocytoma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Advanced Adrenal Gland Pheochromocytoma | Advanced Paraganglioma | Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | Stage...United States
-
Peking Union Medical College HospitalRecruitingPheochromocytoma, Metastatic | Paraganglioma, Malignant | Pheochromocytoma MalignantChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Regional Adrenal Gland PheochromocytomaUnited States
-
Peking Union Medical College HospitalRecruitingUltrasonography | Pheochromocytoma, Metastatic | Paraganglioma, Malignant | Pheochromocytoma MalignantChina
-
Abramson Cancer Center of the University of PennsylvaniaCompletedUnresectable Paraganglioma | Recurrent Pheochromocytoma | Advanced Metastatic Paraganglioma | Advanced Metastatic Pheochromocytoma | Recurrent Paraganglioma | Unresectable PheochromocytomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMetastatic Adrenal Gland Pheochromocytoma | Malignant Adrenal Gland Pheochromocytoma | Malignant ParagangliomaUnited States
-
Peking Union Medical College HospitalCompletedPheochromocytoma, Metastatic | Paraganglioma, Malignant | Pheochromocytoma MalignantChina
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
Kunwu Yan,MMCompletedHemodynamic | Adrenal Pheochromocytoma
-
National Cancer Institute (NCI)TerminatedParaganglioma | Metastatic Adrenal Gland Pheochromocytoma | Recurrent Adrenal Gland Pheochromocytoma | Extra-Adrenal ParagangliomaUnited States, Singapore, Hong Kong
Clinical Trials on Lutetium [177Lu] oxodotreotide/dotatate
-
Sociedad Española de Medicina Nuclear e Imagen...RecruitingDigestive System Diseases | Neoplasms | Neoplasms by Histologic Type | Neoplasms by Site | Endocrine System Diseases | Stomach Neoplasms | Gastrointestinal Neoplasms | Digestive System Neoplasms | Neoplasms, Germ Cell and Embryonal | Endocrine Gland Neoplasms | Neuroectodermal Tumors | Neoplasms, Nerve Tissue | Intestinal Diseases and other conditionsSpain
-
Novartis PharmaceuticalsActive, not recruitingSomatostatin Receptor-positive Neuroendocrine TumorJapan
-
Peking UniversityNot yet recruiting
-
OHSU Knight Cancer InstituteNovartis; Oregon Health and Science UniversityNot yet recruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnMetastatic Adrenal Gland Pheochromocytoma | Stage III Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 | Locally Advanced Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Metastatic Parathyroid Gland Carcinoma and other conditionsUnited States
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
CHU de Quebec-Universite LavalRecruitingNeuroendocrine Tumors | Carcinoma, Neuroendocrine | Carcinoid TumorCanada
-
Novartis PharmaceuticalsRecruitingGlioblastomaSpain, Switzerland, France, Portugal, United States
-
Sinotau Pharmaceutical GroupRecruiting
-
Istituto Scientifico Romagnolo per lo Studio e...Active, not recruiting